MedCity News March 24, 2025
Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies.
Novo Nordisk is expanding its prospects in obesity and other metabolic disorders by securing rights to an early-clinical engineered peptide whose effects comes from activating three receptors — the same three targets hit by a next-generation weight drug in development by rival Eli Lilly.
According to deal terms announced Monday, Novo Nordisk is paying United Biotechnology $200 million up front for global rights to its drug, UBT251. United Biotechnology retains rights to the molecule in...
Today's Sponsors
Today's Sponsor